A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

  • End date
    Apr 21, 2025
  • participants needed
  • sponsor
    Immunitas Therapeutics
Updated on 21 October 2022
monoclonal antibodies
measurable disease
squamous cell carcinoma
endocrine therapy
lung cancer
combination chemotherapy
hormone therapy
folfox regimen
chemotherapy regimen
cancer chemotherapy
solid tumor
triple negative breast cancer
esophagus cancer
platinum-based chemotherapy
lung carcinoma
chop regimen


This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas.

The main goals of this study are to:

  • Find the recommended dose of IMT-009 that can be safely given to participants
  • Learn more about the side effects of IMT-009
  • Learn more about pharmacokinetics of IMT-009
  • Learn more about the effectiveness of IMT-009
  • Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-009


IMT-009 is an Fc-attenuated monoclonal antibody that binds with high affinity and selectivity to CD161, a receptor that is broadly expressed on NK and a subset of memory T cells, blocking interactions between the receptor and its cognate ligand, CLEC2D, which is expressed on the surface of both cancer cells and immune cells. Preclinical data confirm that CD161 blockade with IMT-009 results in enhanced anti-tumor activity. This is a Phase 1/2a, open label dose escalation study of IMT-009, a fully human monoclonal antibody targeting CD161, given as a single agent in Phase 1 and potentially in combination with other antineoplastic agents in Phase 2.

Condition Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, T-cell Lymphoma
Treatment IMT-009
Clinical Study IdentifierNCT05565417
SponsorImmunitas Therapeutics
Last Modified on21 October 2022


Yes No Not Sure

Inclusion Criteria

Phase 1
Males and females ≥18 years of age at the time of consent
Patients who have histologically or cytologically-documented, unresectable locally advanced, or metastatic solid malignancy or designated lymphoma that is progressing or has failed the therapies listed below or who are intolerant of or are ineligible for or refuse standard of care therapy as detailed below
Patients previously pre-treated with a checkpoint inhibitor must be anti-PD-L1 relapsed/refractory defined as having clear evidence of radiologic or clinical progression while on or within 4 months of their last anti-PD-L1 dose
There is no limit to the number of prior treatment regimens a patient may have had prior to enrollment
Has one of the following solid tumor or lymphoma indications
Non-small cell lung cancer (NSCLC) - squamous or non-squamous
Must have received prior chemotherapy and a checkpoint inhibitor (either sequentially or in combination) per PD-L1 status
Must not have a documented EGFR, ALK, ROS, RET, BRAFV600E, Met exon 14 skipping, KRAS mutation
Head and neck squamous cell carcinoma (HNSCC) HPV+ or -
Must have received prior treatment with a platinum-based chemotherapy and a checkpoint inhibitor (either sequentially or in combination) per PD-L1 status
Triple negative breast cancer (TNBC)
Must have received prior treatment with chemotherapy (anthracycline, and/or taxanes, and/or platinum, and/or gemcitabine); in combination with a checkpoint inhibitor if PD-L1+; a PARPi for patients with gBRCA mutations, and sacituzumab govitecan
Cutaneous squamous cell carcinoma
Must have received prior treatment with a checkpoint inhibitor
Hormone receptor positive (HR+) breast cancer
Must have received endocrine therapy, a CDK 4/6 inhibitor (preferably in combination with endocrine therapy in the 1st line or 2nd line setting or as monotherapy), a PI3K inhibitor and endocrine therapy for tumors with PIK3CA activating mutation; and a PARPi for patients with gBRCA mutations
Small bowel carcinoma
Must have received prior treatment with at least one 5FU or capecitabine based regimen (such as but not limited to FOLFOX, FOLFIRI or CAPOX) with or without bevacizumab, and a PD1/PD-L1 inhibitor alone or in combination with CTLA4 inhibitor (for MSI-H or dMMR tumors)
Esophageal cancer
Must have received prior treatment with a platinum-based chemotherapy and a checkpoint inhibitor (either sequentially or in combination per PD-L1 status), and an anti-HER2 agent for patients with known HER2 overexpressing tumors
Colorectal cancer (MSS & MSI-H/dMMR)
Must have received at least one 5FU chemotherapy-based regimen, with bevacizumab or cetuximab/panitumumab, and / or a PD1/PD-L1 (single agent or combination with CTLA4) for dMMR/MSI-H tumors
For patients with known BRAF V600E mutation: must have received prior treatment with a combination of encorafenib and cetuximab or panitumumab
Histologically confirmed diffuse large B cell lymphoma (DLBCL)
Must have received at least 2 prior lines of therapy including prior treatment with chemotherapy and an anti-CD20 antibody (ie, CHOP)
Must be ineligible or refuse therapies with demonstrated clinical benefit such as for example CAR-T or autologous stem cell transplant
Hodgkin lymphoma
Must have received at least 3 prior systemic therapies, including combination chemotherapy (ie, ABVD)
Burkitt lymphoma
Must have received at least 2 prior lines of therapy
Must be ineligible or refuse therapies with demonstrated clinical benefit
T cell lymphoma
Must have received at least 2 prior systemic therapies, including combination chemotherapy (eg, CHOP). 3. Patients with solid tumors have measurable disease based on RECIST 1.1. In
hematological malignancies LYRIC/Lugano will be used
Phase 2A Inclusion criteria for these patients will remain similar to those used during
Phase 1

Exclusion Criteria

Phase 1
Any prior Grade 4 immune-mediated adverse event (imAE) or Grade 3 imAE requiring
steroid treatment (>10 mg/day prednisone or equivalent dose for more than 12 weeks)
while receiving immunotherapy that has been documented within the 12 months prior to
Unresolved toxicity higher than Grade 1 CTCAE v 5 (or higher) attributed to any prior
therapy/procedure at screening, except for alopecia
Prior history of serious hypersensitivity reaction to treatment with a monoclonal
Patients who are currently pregnant or breastfeeding
Use of other investigational drugs (drugs not marketed for any indication) within 14
days or at least 5 half-lives (whichever is shorter) before investigational enrollment
(Day 1, Cycle 1 dosing)
Patient with history of malignancy (other than the one for which he/she participates
in the study or than basal cell carcinoma definitively resected, or other in situ
cancers) - unless the patient has undergone curative therapy with no evidence of that
disease for 3 years
Patients currently receiving cancer therapy (ie, chemotherapy, radiation therapy
immunotherapy, biologic therapy, hormonal therapy, surgery, and/or tumor embolization)
or expected to require any other form of antineoplastic therapy while on study
Patients with active, known or suspected autoimmune disease requiring systemic
treatment (corticosteroids or other active immunosuppressive medications) within the
past 6 months - with the exclusion of vitiligo, resolved asthma/atopia or alopecia
areata; hypothyroidism stable on hormone replacement
Known CNS metastases (unless clinically stable for at least 4weeks prior to enrollment
and off steroids for at least 7 days- exceptions above for physiologic replacement
doses of hydrocortisone)
Myocardial infarction, symptomatic congestive heart failure (NYHA> Class II), unstable
angina, or serious uncontrolled cardiac arrhythmia within the last 6 months of
Patient has history of or current HIV, Hepatitis B or C infection, even if not active
and/or controlled
Phase 2A Exclusion criteria are expected to remain the same as Phase 1 unless there is a
need to further refine expansion cohort populations for Phase 2a. Patients must have a
CD161 and CLEC2D positive tumor demonstrated by the IHC CLIA assay for each analyte
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note